Lu Han

Partner, Lumira Ventures

Role: Associate

Sites: CDL-Oxford, CDL-Toronto, CDL-Vancouver, CDL-Wisconsin

Streams: Advanced Therapies, Biomedical Engineering

Lu Han is a science-driven investor who is passionate about helping entrepreneurs build truly innovative best/first-in-class life science companies. Having started as an analyst, Lu is a Partner at Lumira, focused on deal sourcing, due diligence, company building and global partnership initiatives for Lumira portfolio companies. Prior to joining Lumira, he was a co-founder at Sound Options Tinnitus Treatment Inc., an AI-powered digital therapeutics company that developed a non-invasive treatment for disabling neurological diseases. Prior to this, Lu was a strategic consultant at a boutique consultancy firm in the healthcare and life sciences sector, covering both Canadian and International markets. Lu received his PhD in neuroscience from the University of Toronto followed by post-doctoral studies at the Hospital for Sick Children. He is fluent in English and Mandarin Chinese. Lu is a board director or observer of Lumira Ventures portfolio companies, Amacathera, Deka Biosceinces, LQT Therapeutics, Transposon Therapeutics and Iterion Therapeutics.